As of 2025-12-24, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -7.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,915.14 mil USD. RARE's TTM EBITDA according to its financial statements is -510.37 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 15.2x | 14.0x |
| Forward P/E multiples | 22.1x - 43.4x | 32.8x |
| Fair Price | (122.74) - (86.24) | (129.35) |
| Upside | -453.2% - -348.2% | -472.2% |
| Date | EV/EBITDA |
| 2025-12-22 | -7.67 |
| 2025-12-19 | -7.43 |
| 2025-12-18 | -7.31 |
| 2025-12-17 | -7.38 |
| 2025-12-16 | -7.59 |
| 2025-12-15 | -7.95 |
| 2025-12-12 | -7.95 |
| 2025-12-11 | -7.95 |
| 2025-12-10 | -7.91 |
| 2025-12-09 | -7.96 |
| 2025-12-08 | -7.99 |
| 2025-12-05 | -7.98 |
| 2025-12-04 | -8.01 |
| 2025-12-03 | -7.99 |
| 2025-12-02 | -7.43 |
| 2025-12-01 | -7.41 |
| 2025-11-28 | -7.67 |
| 2025-11-26 | -7.48 |
| 2025-11-25 | -7.44 |
| 2025-11-24 | -7.30 |
| 2025-11-21 | -7.45 |
| 2025-11-20 | -7.00 |
| 2025-11-19 | -7.12 |
| 2025-11-18 | -7.31 |
| 2025-11-17 | -7.25 |
| 2025-11-14 | -7.36 |
| 2025-11-13 | -7.32 |
| 2025-11-12 | -7.44 |
| 2025-11-11 | -7.39 |
| 2025-11-10 | -7.14 |
| 2025-11-07 | -6.89 |
| 2025-11-06 | -6.95 |
| 2025-11-05 | -7.13 |
| 2025-11-04 | -7.24 |
| 2025-11-03 | -7.43 |
| 2025-10-31 | -7.64 |
| 2025-10-30 | -7.75 |
| 2025-10-29 | -7.64 |
| 2025-10-28 | -7.67 |
| 2025-10-27 | -7.78 |
| 2025-10-24 | -7.44 |
| 2025-10-23 | -7.46 |
| 2025-10-22 | -7.37 |
| 2025-10-21 | -7.57 |
| 2025-10-20 | -7.60 |
| 2025-10-17 | -7.27 |
| 2025-10-16 | -7.52 |
| 2025-10-15 | -7.42 |
| 2025-10-14 | -7.09 |
| 2025-10-13 | -7.16 |